Open AccessPrevalence of Pathologic N2/N3 Disease in Postmenopausal Women with Clinical N0 ER+/HER2− Breast Cancer
Author(s) -
Maire J. Amlicke,
Jihye Park,
Chris B. Agala,
Dana L. Casey,
Emily Ray,
Stephanie Downs-Canner,
Philip M. Spanheimer
Publication year - 2022
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-022-12056-4
Subject(s) - medicine , breast cancer , surgical oncology , cancer , stage (stratigraphy) , odds ratio , disease , biopsy , oncology , gynecology , paleontology , biology
The RxPONDER trial demonstrated that the 21-gene recurrence score can be used to guide adjuvant systemic therapy decisions in postmenopausal women with pN1 ER+/HER2- breast cancer. As such, a sentinel lymph node biopsy (SLNB) may not provide systemic treatment-altering information for many patients, and omission of SLNB in patients with low probability of pN2/N3 disease could be considered.